PTC Therapeutics Names SVP & GM

Eric Pauwels has been appointed senior vice president and general manager of commercial operations, Americas, PTC Therapeutics. Mr. Pauwels will be responsible for the commercial strategy, organizational build out and launch of Translarna for genetic disorders in the U.S., Canada and Latin America. 
 
Mr. Pauwels brings 33 years of global healthcare experience from several top U.S. and global pharmaceutical companies. Most recently, he was chief commercial officer at NPS Pharmaceuticals and president of NPS Pharmaceuticals International. At NPS, he built global commercial operations for the launch of Gattex/Revestive and prepared the pre-launch strategy for Natpara, both orphan biologic therapies approved by the FDA for rare gastrointestinal and endocrine diseases. From 2005 to 2010, he served as senior vice president, Global Commercial Operations, at Shire Human Genetic Therapies, with oversight of more than 400 employees in 30 countries. He also held global marketing and management roles with Shire, Bayer, Fournier, and J&J.
 
“Eric is an exceptional individual who has successfully launched more than 20 biopharmaceutical specialty and rare disease products globally,” said Mark Rothera, chief commercial officer, PTC Therapeutics. “His strong track record of strategic leadership, operational execution and global commercial expertise, particularly in orphan drug launches, will be extremely valuable as we work toward the launch of Translarna in the U.S. and other key markets. I am proud of the high caliber commercial leadership team we have built at PTC that will ensure we bring Translarna to patients around the world as quickly as possible.”